AREVA Med initiates Phase I Clinical Trial of anti-cancer treatment with lead-212

AREVA Med announced on August 4 that it had started a Phase 1 clinical trial in the United States for its new cancer treatment product.

Before new medicines are marketed and made available to doctors and patients, they must be proven safe and therapeutically effective through an extensive series of clinical trials carried out in three phases. At the end of each phase, the collected data are analyzed and used to design the following phase.

The Phase 1 trial being conducted at the University of Alabama at Birmingham (UAB) will allow researchers to study the behavior of the new product in patients and obtain initial information concerning its safety, effects and maximum dosages.

Patrick Bourdet, President and CEO of AREVA Med, said: “After several years of intense work and multiple innovations, we are delighted to begin this important trial with our alpha emitting lead-212 and to be working with the UAB, one of the leading cancer centers for radioimmunotherapy. We hope this clinical trial will contribute to numerous innovative therapies to combat cancer.”